ライフサイエンスコーパス: lymphadenectomy

1 plus distal gastrectomy and retroperitoneal lymphadenectomy).

2 uding distal gastrectomy and retroperitoneal lymphadenectomy).

3 plus distal gastrectomy and retroperitoneal lymphadenectomy).

4 s compared with D2 resection (levels 1 and 2 lymphadenectomy).

5 py, transthoracic esophagectomy, and 2-field lymphadenectomy.

6 d thyroid cancer, necessitating central neck lymphadenectomy.

7 of minimal access surgery for resection and lymphadenectomy.

8 , evidence supports the need for an adequate lymphadenectomy.

9 ations in patients who have a less extensive lymphadenectomy.

10 denectomy, and (2) from this, define optimum lymphadenectomy.

11 survival improved with increasing extent of lymphadenectomy.

12 egative FDG-PET/CT was confirmed by complete lymphadenectomy.

13 cancer and identifies patients for selective lymphadenectomy.

14 ositive nodes more frequently than a limited lymphadenectomy.

15 etastases, eliminating the need for invasive lymphadenectomy.

16 actors associated with obtaining an adequate lymphadenectomy.

17 those patients who did not have an adequate lymphadenectomy.

18 utic benefits of a complete versus selective lymphadenectomy.

19 ificantly less likely to receive an adequate lymphadenectomy.

20 on radical cystectomy with bilateral pelvic lymphadenectomy.

21 whose survival can be prolonged by immediate lymphadenectomy.

22 ts underwent PET/CT and pelvic and abdominal lymphadenectomy.

23 nsthoracic en bloc esophagectomy and 2-field lymphadenectomy.

24 lymphadenectomy with or without para-aortic lymphadenectomy.

25 ify and optimize the therapeutic benefits of lymphadenectomy.

26 o be related to surgical practice, primarily lymphadenectomy.

27 identifying patients who would benefit from lymphadenectomy.

28 hick primary cutaneous melanoma and sentinel lymphadenectomy.

29 onal study of esophagectomy with three-field lymphadenectomy.

30 lihood of lymph node metastases and requires lymphadenectomy.

31 lvic disease before planned surgical staging lymphadenectomy.

32 dentifies those who may benefit from earlier lymphadenectomy.

33 and group 3-a minimal abdominal and thoracic lymphadenectomy.

34 All patients underwent a complete axillary lymphadenectomy.

35 identification of all SLNs during selective lymphadenectomy.

36 patients undergoing mastectomy and inguinal lymphadenectomy.

37 ewer patients to the morbidity of a complete lymphadenectomy.

38 be reviewed to determine the true extent of lymphadenectomy.

39 ndorse CA in selected patients undergoing D2 lymphadenectomy.

40 epresent a valuable tool for guiding salvage lymphadenectomy.

41 radical prostatectomy with bilateral pelvic lymphadenectomy.

42 d has been used as a surrogate for extent of lymphadenectomy.

43 ases who may benefit from immediate complete lymphadenectomy.

44 ection, whereas others only rarely recommend lymphadenectomy.

45 de count as a surrogate for a well performed lymphadenectomy.

46 tion (MILND) is a novel approach to inguinal lymphadenectomy.

47 inel lymph node biopsy, and inguinal femoral lymphadenectomy.

48 vity (20.5% vs 25.9%, P = 0.01) and improved lymphadenectomy (16 vs 11 nodes, P < 0.01).

49 ic resections or gastrinoma enucleation with lymphadenectomy, 2 patients also had synchronous resecti

50 Within 3 months of sentinel lymphadenectomy, 270 (86.0%) of the 314 SLN-positive pat

51 Despite complete lymphadenectomy, 5-year overall survival (OS) for patien

52 ajor hepatectomy (82%), often accompanied by lymphadenectomy (67%) and sometimes by extrahepatic bile

53 A meticulous surgical lymphadenectomy adhering to well defined surgical bounda

54 retrieved and to determine if the extent of lymphadenectomy affects stage allocation and influences

55 The value of an extended lymphadenectomy after nCRT for esophageal cancer is deba

56 gional nodes, it is unclear whether extended lymphadenectomy after nCRT is still useful.

57 question the indication for maximization of lymphadenectomy after nCRT.

58 sthoracic esophagectomy with en bloc 2-field lymphadenectomy after neoadjuvant therapy were included,

59 Immediate complete axillary lymphadenectomy (ALND) after sentinel lymphadenectomy (S

60 ned in patients undergoing complete axillary lymphadenectomy (ALND).

61 ment have a low probability of survival with lymphadenectomy alone.

62 red with those who had hepatic resection and lymphadenectomy alone.

63 t draining cervical lymph nodes, as cervical lymphadenectomy also inhibited CD4(+) T cell-mediated dr

64 The absence of lymphadenectomy and assignment of histologic grade were

65 s who underwent hepatic resection along with lymphadenectomy and extra hepatic biliary resection had

66 ients who had undergone prostatectomy with a lymphadenectomy and had disease, as assessed on patholog

67 we discuss the complications associated with lymphadenectomy and identify subsets of low-risk patient

68 rgone excision of the extrahepatic duct with lymphadenectomy and liver resection.

69 , necessity for vascular resection, regional lymphadenectomy and measures to minimize blood loss and

70 patients were surgically staged with pelvic lymphadenectomy and none received hormonal therapy befor

71 f 80 patients who underwent bilateral pelvic lymphadenectomy and radical cystectomy for bladder cance

72 es no difference in 5-year survival, however lymphadenectomy and reported surgical quality was subopt

73 , surgical resectional techniques, extent of lymphadenectomy and setting of specialized units and mul

74 he surgical techniques, improved adequacy of lymphadenectomy and some other minor factors such as mul

75 al Question: What is the association between lymphadenectomy and survival, disease recurrence, and su

76 iochemotherapy followed by complete regional lymphadenectomy and two postoperative courses of biochem

77 obot-assisted radical cystectomy with pelvic lymphadenectomy and urinary diversion for the treatment

78 o underwent radical prostatectomy and pelvic lymphadenectomy and who were found to have nodal metasta

79 relationship between survival and extent of lymphadenectomy, and (2) from this, define optimum lymph

80 ded endoscopic peritoneoscopy, liver biopsy, lymphadenectomy, and abdominal exploration.

81 thoracic nodes, group 2-a minimal abdominal lymphadenectomy, and group 3-a minimal abdominal and tho

82 ingle fraction of 20 Gy radiation, popliteal lymphadenectomy, and lymphatic vessel ablation.

83 However, issues like extent of resection, lymphadenectomy, and minimal access approach are still t

84 tive plan, including thyroidectomy, possible lymphadenectomy, and postoperative radioactive iodine ad

85 began vaccine therapy within 4 months after lymphadenectomy, and who had more complete data on the s

86 treated with radical hysterectomy and pelvic lymphadenectomy, and who had positive pelvic lymph nodes

87 benefits of radical cystectomy with extended lymphadenectomy, and will also examine the latest surgic

88 Pelvic lymphadenectomy appears to provide adequate nodal yield

89 benefits obtained by extending the limits of lymphadenectomy are compelling but inconclusive.

90 of adjuvant therapy should include extent of lymphadenectomy as a stratification factor.

91 Adequate lymphadenectomy, as measured by analysis of at least 15

92 934 melanoma patients who underwent sentinel lymphadenectomy at our institution from 1996 to 2003.

93 of life, and the optimal standard for pelvic lymphadenectomy at surgery.

94 etropubic prostatectomy and bilateral pelvic lymphadenectomy at the Mayo Clinic.

95 ale for surgeons to perform a more extensive lymphadenectomy at the time of initial thyroidectomy and

96 tomy as well as the optimal extent of pelvic lymphadenectomy at the time of radical cystectomy.

97 ph nodes and may benefit most from selective lymphadenectomy, avoiding the unnecessary complications

98 servative type of lymph node dissection), D2 lymphadenectomy (but not D3) is associated with better d

99 Laparoscopic prostatectomy with extended lymphadenectomy can be performed safely, retrieves a hig

100 Lymphatic mapping and sentinel lymphadenectomy can be successfully learned and applied

101 ion (WE) plus LM/SNB with immediate complete lymphadenectomy (CLND) for sentinel node (SN) metastases

102 e undergone radical prostatectomy and pelvic lymphadenectomy compared with those who received ADT onl

103 astases who have undergone prostatectomy and lymphadenectomy, compared with those who receive deferre

104 of LN metastasis, the extent of surgery and lymphadenectomy could be limited and follow-up adjusted

105 vidence from randomised trials that extended lymphadenectomy (D2 gastric resection) confers a surviva

106 Comparative lymphadenectomy data for kidney and upper tract urotheli

107 elvic lymph node status, and extended pelvic lymphadenectomy dissection was necessary on the opposite

108 rextensive pelvic resection (extended pelvic lymphadenectomy dissection) in patients with localized P

109 Routine lymphadenectomy does not appear to yield benefit in kidn

110 rom randomized clinical trials suggests that lymphadenectomy does not improve survival or decrease di

111 Extended lymphadenectomy does not seem to confer a significant ov

112 , indicating a therapeutic value of extended lymphadenectomy during esophagectomy.

113 Lymphadenectomy during oesophageal cancer surgery is a s

114 he data provide support in favor of extended lymphadenectomy during potentially curative gastrectomy

115 important prognostic and therapeutic role of lymphadenectomy during radical cystectomy has become app

116 The prognostic role of the extent of lymphadenectomy during surgery for esophageal cancer is

117 This study indicated that the extent of lymphadenectomy during surgery for esophageal cancer mig

118 The prognostic role of lymphadenectomy during surgery for oesophageal cancer is

119 between 1965 and 2009 that compared extended lymphadenectomy (EL) with standard rectal resection.

120 , WLE plus SLND (SLND), or WLE plus elective lymphadenectomy (ELND) for primary melanoma.

121 with breast cancer were staged with sentinel lymphadenectomy followed by completion level I and II ax

122 Of 2,602 patients who underwent complete lymphadenectomy for AJCC stage III melanoma with regiona

123 who undergo radical hysterectomy and pelvic lymphadenectomy for carcinoma of the cervix.

124 n endoscopic mucosectomy or gastrectomy with lymphadenectomy for early gastric cancer depends especia

125 s) represents a quality assurance measure in lymphadenectomy for many solid tumors, the minimum numbe

126 who underwent lymphatic mapping and sentinel lymphadenectomy for melanoma and were followed up for at

127 g times has guided the extent of surgery and lymphadenectomy for MTC.

128 ion and sentinel-node biopsy, with immediate lymphadenectomy for nodal metastases detected on biopsy

129 ent between subjects randomized to SLNB with lymphadenectomy for nodal metastasis on biopsy and subje

130 go wide excision and nodal observation, with lymphadenectomy for nodal relapse (observation group), o

131 and subjects randomized to observation with lymphadenectomy for nodal relapse.

132 34 underwent curative resection and regional lymphadenectomy for pathologically staged IE or IIE-1 (p

133 high-risk patients, enabling restriction of lymphadenectomy for patients with a low risk of aggressi

134 erapy after radical cystectomy and bilateral lymphadenectomy for patients with muscle-invasive urothe

135 ers, whereas minimally invasive ilioinguinal lymphadenectomy for penile cancer remains exploratory at

136 dical records on 2526 patients who underwent lymphadenectomy for regional LN metastasis associated wi

137 Patients had undergone lymphadenectomy for regional LN metastasis.

138 erienced hands, laparoscopic retroperitoneal lymphadenectomy for renal cell cancer is safe and allows

139 treated by radical cystectomy and bilateral lymphadenectomy for urothelial-cell carcinoma of the bla

140 A minimal lymphadenectomy (groups 1, 2, and 3) was projected to le

141 therapy but the effectiveness and extent of lymphadenectomy has been challenged, and its acceptance

142 As a pelvic lymphadenectomy has complications that generally increas

143 me the predominant approach, use of extended lymphadenectomy has increased with lymph node yield near

144 with elevated markers before retroperitoneal lymphadenectomy have a high rate of relapse and should b

145 invasive disease, nodal status and extent of lymphadenectomy have been shown to correlate with surviv

146 sion and sentinel-node biopsy with immediate lymphadenectomy if nodal micrometastases were detected o

147 ive observation of regional lymph nodes with lymphadenectomy if nodal relapse occurred, or to wide ex

148 intraoperative lymphatic mapping followed by lymphadenectomy if the sentinel node is positive.

149 urthermore, previous studies have shown that lymphadenectomy impairs acquisition of adaptive immune r

150 erapy after radical prostatectomy and pelvic lymphadenectomy improves survival and reduces the risk o

151 uggested that the performance of an extended lymphadenectomy in association with a pancreaticoduodena

152 uggested that the performance of an extended lymphadenectomy in association with a pancreaticoduodena

153 Minimally invasive lymphadenectomy in bladder cancer does not yet approach

154 compared with the gold standard of complete lymphadenectomy in detecting metastatic disease for endo

155 traoperative pathological analyses mean that lymphadenectomy in low-risk patients might still have me

156 he possible therapeutic benefit of selective lymphadenectomy in management of patients with apparent

157 consideration when monitoring the quality of lymphadenectomy in melanoma and can represent entry crit

158 y and the need for extended pelvic and iliac lymphadenectomy in order to optimize an integrated treat

159 sthoracic esophagectomy with en bloc 2-field lymphadenectomy in patients post neoadjuvant chemotherap

160 ew minimally invasive procedure for inguinal lymphadenectomy in patients with penis cancer.

161 dectomy and to consider reoperative cervical lymphadenectomy in patients with persistently elevated c

162 se the current literature on the benefits of lymphadenectomy in patients with renal cell carcinoma.

163 The independent role of the extent of lymphadenectomy in relation to all-cause and disease-spe

164 sion with a 2-cm margin and undergo elective lymphadenectomy in selected circumstances.

165 a reasonable alternative to inguinal femoral lymphadenectomy in selected women with squamous cell car

166 The extent of lymphadenectomy in surgical procedures should respect th

167 f patients undergoing unnecessary, extensive lymphadenectomy in the absence of disease.

168 definition of limited versus extended pelvic lymphadenectomy in the literature is variable, and the i

169 assess the value of extended lateral pelvic lymphadenectomy in the operative management of rectal ca

170 ial cancer metastases and can safely replace lymphadenectomy in the staging of endometrial cancer.

171 The role of esophagectomy with radical lymphadenectomy in the treatment of esophageal cancer is

172 Standardization of pelvic lymphadenectomy in the urologic community is strongly ne

173 nts of lymph node dissection (D1, D2, and D3 lymphadenectomy) in patients affected with operable gast

174 rian or endometrial cancer), after a staging lymphadenectomy including resection of SNs related to th

175 e patients than lesser anatomic templates of lymphadenectomy, including some patients with common ili

176 Sentinel lymphadenectomy is a highly accurate technique for ident

177 Furthermore lymphadenectomy is associated with an increase in both s

178 Lymphadenectomy is effective for nodal metastasis from M

179 Adequate lymphadenectomy is essential to ensure correct stage all

180 urothelial cancers remain muddled as routine lymphadenectomy is not performed and both open and lapar

181 Concomitant regional lymphadenectomy is of prognostic value, however it is no

182 Lymphadenectomy is performed to assess patient prognosis

183 25 years, it is no longer clear that pelvic lymphadenectomy is pertinent for most men diagnosed toda

184 Selective lymphadenectomy is widely accepted in the management of

185 ntraoperative lymphatic mapping and sentinel lymphadenectomy (LM/SL) for identification of occult lym

186 Lymphatic mapping and sentinel lymphadenectomy (LM/SL) have been applied to virtually a

187 Lymphatic mapping and sentinel lymphadenectomy (LM/SL) is standard to stage regional no

188 ntraoperative lymphatic mapping and sentinel lymphadenectomy (LM/SL), the SN is the only tumor-involv

189 ent predictor of margin status or suboptimal lymphadenectomy (<12 lymph nodes harvested).

190 Lymphadenectomy may have beneficial effects on PFS in op

191 is is used to determine the need for further lymphadenectomy, more sensitive intraoperative methods w

192 Furthermore, the extent of lymphadenectomy must be correlated with node location, w

193 mice underwent lymphadenectomy (n = 5), sham lymphadenectomy (n = 5), or no intervention (n = 5), fol

194 study lymphatic flow, C57BL/6 mice underwent lymphadenectomy (n = 5), sham lymphadenectomy (n = 5), o

195 to assess effects of the extent of selective lymphadenectomy on outcomes in women with apparent stage

196 the potentially positive effect of extended lymphadenectomy on survival have been performed in patie

197 stic benefits by extending the boundaries of lymphadenectomy or by increasing the number of nodes exc

198 g preoperative data, and patients in whom no lymphadenectomy or reconstruction was performed were exc

199 tality, independent of the categorization of lymphadenectomy or stratification for T category, calend

200 Following standard lymphadenectomy, patients were treated with DNP vaccine

201 ocedure including hysterectomy and selective lymphadenectomy (pelvic or pelvic + aortic).

202 Compartment-oriented lymphadenectomy performed early in the course of MTC is

203 sisted radical cystectomy (RARC) with pelvic lymphadenectomy (PLND) and urinary diversion for the tre

204 Radical cystectomy and pelvic lymphadenectomy (PLND) remains the standard treatment fo

205 aparoscopic radical cystectomy with extended lymphadenectomy provides short-term functional and oncol

206 ery performed, overall blood loss, extent of lymphadenectomy, rate of resections with negative margin

207 terine carcinoma, the benefits of a complete lymphadenectomy remain controversial.

208 Lymphadenectomy remains the best method to stage prostat

209 Radical cystectomy with thorough pelvic lymphadenectomy remains the gold standard for management

210 e needed to properly establish the extent of lymphadenectomy required to obtain such benefits.

211 Debate continues regarding the extent of lymphadenectomy required when carrying out an esophagect

212 rveillance, chemotherapy, or retroperitoneal lymphadenectomy (RPLND) with similar survival outcomes.

213 y curable gastric cancer, including extended lymphadenectomy, seems in retrospective surveys to give

214 enerally increase with extent of dissection, lymphadenectomy should be limited to patients at an incr

215 is pertinent, it is unclear how extensive a lymphadenectomy should be performed.

216 metastases at the time of operation, central lymphadenectomy should be performed.

217 Lymphadenectomy should be strongly considered for ICC, b

218 Therefore, an extended lymphadenectomy should be the standard of care after nCR

219 ection of axillary metastases using sentinel lymphadenectomy (SLND) and immunohistochemistry.

220 illary lymphadenectomy (ALND) after sentinel lymphadenectomy (SLND) has confirmed that tumor-negative

221 European investigators suggest that sentinel lymphadenectomy (SLND), a mainstay of melanoma diagnosis

222 -3 N1-3 M0) radical prostatectomy and pelvic lymphadenectomy specimens.

223 ith stratification for participating centre, lymphadenectomy, stage of cancer, and histological type.

224 tes and a key summary on the developments in lymphadenectomy templates in kidney, prostate and bladde

225 s higher among those who underwent immediate lymphadenectomy than among those in whom lymphadenectomy

226 Clinical Application: Compared with D1 lymphadenectomy (the most conservative type of lymph nod

227 y site were removed at the time of selective lymphadenectomy, the authors used intraoperative radioly

228 hether all low-risk patients need a complete lymphadenectomy, the limitations of preoperative and int

229 of a distal gastrectomy and retroperitoneal lymphadenectomy to a pylorus-preserving pancreaticoduode

230 tal gastrectomy and extended retroperitoneal lymphadenectomy to a standard pancreaticoduodenectomy) c

231 metastases suggesting that a more systematic lymphadenectomy to extirpate occult disease may be indic

232 What constitutes optimum lymphadenectomy to maximize survival is controversial be

233 domly assigned after radical nephrectomy and lymphadenectomy to observation or to interferon alfa-NL

234 egan the international Multicenter Selective Lymphadenectomy Trial (MSLT) 5 years ago to evaluate the

235 egan the international Multicenter Selective Lymphadenectomy Trial (MSLT-I) to compare 2 treatment ap

236 nterim analysis of the Multicenter Selective Lymphadenectomy Trial 1 (MSLT-1).

237 SLNB in melanoma, the Multicenter Selective Lymphadenectomy Trial I was performed.

238 subject of the ongoing Multicenter Selective Lymphadenectomy Trial II.

239 The phase III Multicenter Selective Lymphadenectomy Trial will definitively settle the issue

240 r undergoing radical hysterectomy and pelvic lymphadenectomy using preoperative and intraoperative ly

241 ected prognosis of carrying out less radical lymphadenectomies was calculated according to 3 groups:

242 0 cancers and 1 to 6 nodes positive, optimum lymphadenectomy was 10 for pT1, 15 for pT2, and 29 to 50

243 ymphadenectomy was defined for pTis; optimum lymphadenectomy was 10 to 12 nodes for pT1, 15 to 22 for

244 after orchiectomy and before retroperitoneal lymphadenectomy was a significant independent predictor

245 Greater extent of lymphadenectomy was associated with increased survival f

246 A threshold for an adequate lymphadenectomy was defined as retrieval of 12 nodes.

247 In pN0M0 cancers, no optimum lymphadenectomy was defined for pTis; optimum lymphadene

248 ate lymphadenectomy than among those in whom lymphadenectomy was delayed (72.3+/-4.6% vs. 52.4+/-5.9%

249 omy was done in 340 patients and para-aortic lymphadenectomy was done in 196 (58%) of these patients.

250 inel-lymph-node mapping with complete pelvic lymphadenectomy was done in 340 patients and para-aortic

251 agectomy with two-field (abdomen and thorax) lymphadenectomy was done within 4-6 weeks of completion

252 One patient who did not undergo lymphadenectomy was excluded from the pathology data ana

253 Performance of aortic selective lymphadenectomy was not associated with survival.

254 The extent of lymphadenectomy was not statistically significantly asso

255 rwent sentinel lymph node biopsy; completion lymphadenectomy was performed for patients with sentinel

256 Between 1991 and 1997, axillary lymphadenectomy was performed in 157 women with a tumor-

257 Lymphadenectomy was performed in 248 patients (55%); 74

258 Extended (D2) lymphadenectomy was performed in 75% of cases.

259 Adequate lymphadenectomy was significantly more likely in patient

260 e capable of metastasizing and therefore, if lymphadenectomy was still adequate.

261 ised controlled trial, D1 resection (level 1 lymphadenectomy) was compared with D2 resection (levels

262 (PSMA) HBED-CC PET/CT or PET/MR and salvage lymphadenectomy were retrospectively included.

263 ology, the efficacy, safety, and adequacy of lymphadenectomy were reviewed for studies about prostate

264 IIIB) who were melanoma-free after standard lymphadenectomy were treated with multiple intradermal i

265 Our data thus show a prognostic relevance of lymphadenectomy which should therefore be retained until

266 This study suggests that extended lymphadenectomy with dissection of the nerve plexus does

267 ntinel-lymph-node mapping followed by pelvic lymphadenectomy with or without para-aortic lymphadenect

268 e cancer as well as bladder cancer, extended lymphadenectomy with resection of external and internal

269 sease after radical cystectomy and bilateral lymphadenectomy, with no evidence of any microscopic res

270 dical cystectomy with bilateral pelvic iliac lymphadenectomy, with the intent to cure, for transition